

## TABLE OF CONTENTS

### Continuing Medical Education

- 235 **CME** Pediatric allergic contact dermatitis. Part I: Clinical features and common contact allergens in children  
*Holly Neale, BS, Anna Cristina Garza-Mayers, MD, PhD, Idy Tam, MS, and JiaDe Yu, MD*
- 245 **CME examination**
- 246 Answers to CME examination (Identification No. JA0221), February 2021 issue of the *Journal of the American Academy of Dermatology*
- 247 **CME** Pediatric allergic contact dermatitis. Part 2: Patch testing series, procedure, and unique scenarios  
*Holly Neale, BS, Anna Cristina Garza-Mayers, MD, PhD, Idy Tam, MS, and JiaDe Yu, MD*
- 255 Answers to CME examination (Identification No. JB0221), February 2021 issue of the *Journal of the American Academy of Dermatology*
- 256 **CME examination**

### Letter from the Editor

- 257 American Academy of Dermatology and National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis  
*Dirk M. Elston, MD*

### This Month in JAAD

- 259 This Month in JAAD—February 2021  
*Dirk M. Elston, MD*

### This Month in JAAD Case Reports

- 261 February 2021: This Month in JAAD Case Reports  
*Brett Sloan, MD*

### This Month in JAAD International

- 262 February 2021: Public outreach, risk perceptions, and behavioral change: Skin-lightening agent use in Ghana  
*Jonathan Kantor, MD, MSCE*

<b>A Clinician's Perspective</b>	<b>263</b>	<p>Progress toward diminishing the murkiness of Merkel cell carcinoma management</p> <p><i>Warren R. Heymann, MD</i></p>
<hr style="border-top: 1px dotted #0070C0;"/>		
<b>From the Dermatology Foundation</b>	<b>265</b>	<p>Sleep disturbance in adults with chronic pruritic dermatoses is associated with increased C-reactive protein levels</p> <p>Bottom line: Clinicians should consider the potential for sleep-related and cardiac comorbidities among patients with chronic pruritic dermatoses to reduce the risk of further medical morbidity.</p> <p><i>Sagar P. Patel, MD, Raveena Khanna, BA, Justin Choi, BA, Kyle A. Williams, BS, Youkyung S. Roh, BA, Michael S. Hong, BS, Nishadh H. Sutaria, BS, Thomas Pritchard, MPH, Madan M. Kwatra, PhD, and Shawn G. Kwatra, MD</i></p>
<hr style="border-top: 1px dotted #0070C0;"/>		
<b>Original Articles</b>	<b>273</b>	<p>Association of interleukin-6 and tumor necrosis factor-<math>\alpha</math> with mortality in hospitalized patients with cancer</p> <p>Bottom line: Hospitalized patients with cancer with rash and elevated interleukin-6 and tumor necrosis factor-<math>\alpha</math> levels have a nearly 6 times decreased overall survival. Given the availability of tumor necrosis factor <math>\alpha</math> and interleukin 6 inhibitors, these biomarkers may serve as potential therapeutic targets.</p> <p><i>Joseph R. Stoll, BTL, Toral S. Vaidya, MPH, Shoko Mori, MD, Stephen W. Dusza, DrPH, Mario E. Lacouture, MD, and Alina Markova, MD</i></p>
	<b>283</b>	<p>Initial validation of the product of the signs global assessment and body surface area in atopic dermatitis</p> <p>Bottom line: This is a valid and feasible outcome measure for quickly measuring the signs of atopic dermatitis in clinical practice, improving patient assessment and follow-up.</p> <p><i>Christina Topham, BS, Dylan Haynes, BS, Molly Brazil, BS, and Eric Simpson, MD, MCR</i></p>
	<b>290</b>	<p>Risk of systemic infections in adults with atopic dermatitis: A nationwide cohort study</p> <p>Bottom line: Clinicians should be aware of the increased risk of musculoskeletal, heart, and respiratory tract infections when treating adults with AD.</p> <p><i>Catherine Droitcourt, MD, PhD, Ida Vittrup, MD, Sandrine Kerbrat, MPH, Alexander Egeberg, MD, PhD, and Jacob P. Thyssen, MD, PhD</i></p>
	<b>300</b>	<p>Dupilumab and the risk of conjunctivitis and serious infection in patients with atopic dermatitis: A propensity score–matched cohort study</p> <p>Bottom line: Although dupilumab shows a low risk of serious infections compared to methotrexate, cyclosporine, or mycophenolate, it is associated with at least a doubling in the 6-month risk of conjunctivitis.</p> <p><i>Maria C. Schneeweiss, MD, Seoyoung C. Kim, MD, ScD, Richard Wyss, PhD, Sebastian Schneeweiss, MD, ScD, and Joseph F. Merola, MD, MMSc</i></p>

- 312**      **Quantitative metastatic lymph node burden and survival in Merkel cell carcinoma**  
 Bottom line: Number of metastatic lymph nodes should be the foundation of nodal classification in this disease and may eventually drive adjuvant treatment decisions.  
*Anthony T. Nguyen, MD, PhD, Michael Luu, MPH, Diana J. Lu, MD, Omid Hamid, MD, Jon Mallen-St. Clair, MD, PhD, Mark B. Faries, MD, Nima M. Gharavi, MD, PhD, Allen S. Ho, MD, and Zachary S. Zumsteg, MD*
- 321**      **Improved survival in women versus men with merkel cell carcinoma**  
 Bottom line: More research is needed to investigate the underlying biological and immunologic differences that may account for these survival differences.  
*Moses Tam, MD, Michael Luu, MPH, Christopher A. Barker, MD, Nima M. Gharavi, MD, PhD, Omid Hamid, MD, Stephen L. Shiao, MD, PhD, Anthony T. Nguyen, MD, PhD, Diana J. Lu, MD, Allen S. Ho, MD, and Zachary S. Zumsteg, MD*
- 330**      **Clinical benefit of baseline imaging in Merkel cell carcinoma: Analysis of 584 patients**  
 Bottom line: Baseline imaging frequently changes management in patients with clinically node-negative as well as node-positive MCC.  
*Neha Singh, BS, Nora A. Alexander, BS, Kristina Lachance, MS, Christopher W. Lewis, MD, Aubriana McEvoy, MD, Gensuke Akaike, MD, David Byrd, MD, Sanaz Behnia, MD, Shailender Bhatia, MD, Kelly G. Paulson, MD, PhD, and Paul Nghiem, MD, PhD*
- 340**      **Narrow excision margins are appropriate for Merkel cell carcinoma when combined with adjuvant radiation: Analysis of 188 cases of localized disease and proposed management algorithm**  
 Bottom line: If adjuvant radiotherapy therapy is planned, narrower surgical margins are adequate, reduce morbidity, and minimize delay in initiating radiotherapy.  
*Erica S. Tarabaskar, MD, Teresa Fu, MD, Kristina Lachance, MS, Daniel S. Hippe, MS, Thomas Pulliam, BS, Hannah Thomas, BS, Janet Y. Li, MD, Christopher W. Lewis, MD, Coley Doolittle-Amieva, PA, David R. Byrd, MD, Jeremy T. Kampp, MD, Upendra Parvathaneni, MD, and Paul Nghiem, MD, PhD*
- 348**      **Oral forms of secondary syphilis: An illustration of the pitfalls set by the great imitator**  
 Bottom line: Clinicians confronted with subacute oral lesions in such patients should bear in mind the possibility of this contagious, curable, and sometimes severe disease. This article highlights that oral manifestations can be isolated and this may delay the diagnosis of secondary syphilis.  
*Alexandre Lampros, MD, Vannina Seta, MD, Phillippe Gerhardt, MD, Camille Isnard, MD, Corinne Husson, MD, and Nicolas Dupin, MD*
- 354**      **Evaluation of the fragility of pivotal trials used to support US Food and Drug Administration approval for plaque psoriasis**  
 Bottom line: Additional consideration regarding trial design with more emphasis on conservation of resources in psoriasis is appropriate.  
*Sophia Z. Shalhout, PhD, Romi Bloom, MD, Lynn Drake, MD, and David M. Miller, MD, PhD*

- 361** Validation of a 40-gene expression profile test to predict metastatic risk in localized high-risk cutaneous squamous cell carcinoma  
Bottom line: Incorporation of 40-GEP prognostication into clinical practice could support risk-aligned patient management decisions by complementing current staging systems.  
*Ashley Wysong, MD, MS, Jason G. Newman, MD, Kyle R. Covington, PhD, Sarah J. Kurley, PhD, Sherrif F. Ibrahim, MD, PhD, Aaron S. Farberg, MD, Anna Bar, MD, Nathan J. Cleaver, DO, Ally-Khan Somani, MD, PhD, David Panther, MD, David G. Brodland, MD, John Zitelli, MD, Jennifer Toyohara, MD, Ian A. Maher, MD, Yang Xia, MD, Kristin Bibee, MD, Robert Griego, MD, Darrell S. Rigel, MD, Kristen Meldi Plasseraud, PhD, Sarah Estrada, MD, Lauren Meldi Sholl, MS, Clare Johnson, RN, Robert W. Cook, PhD, Chrysalyn D. Schmults, MD, MSCE, and Sarah T. Arron, MD, PhD*
- 370** Cross-sectional study of blood biomarkers of patients with moderate to severe alopecia areata reveals systemic immune and cardiovascular biomarker dysregulation  
Bottom line: These data may be critical for providing patients with alopecia areata access to systemic treatments and for further development of targeted therapeutic approaches for various alopecia areata subgroups.  
*Jacob W. Glickman, MA, Celina Dubin, BA, Yael Renert-Yuval, MD, Dante Dahabreh, BA, Grace W. Kimmel, MD, Kelsey Auyeung, BA, Yeri D. Estrada, BS, Giselle Singer, BS, James G. Krueger, MD, PhD, Ana B. Pavel, PhD, and Emma Guttman-Yassky, MD, PhD*
- 381**  The dermoscopic inverse approach significantly improves the accuracy of human readers for lentigo maligna diagnosis  
Bottom line: Training in this method improved sensitivity for the diagnosis of LM from 51.5% to 83.6%, making it a useful tool.  
*Aimilios Lallas, MD, PhD, Konstantinos Lallas, MD, Philipp Tschandl, MD, PhD, Harald Kittler, MD, PhD, Zoe Apalla, MD, PhD, Caterina Longo, MD, PhD, and Giuseppe Argenziano, MD, PhD*
- 390** Treating toxic epidermal necrolysis with systemic immunomodulating therapies: A systematic review and network meta-analysis  
Bottom line: Combination therapy with corticosteroids and intravenous immune globulin should be considered by clinicians to treat toxic epidermal necrolysis.  
*Tsung-Yu Tsai, MD, I-Hsin Huang, MD, Yuan-Chen Chao, MD, Hua Li, MA, Tyng-Shiuan Hsieh, MD, Hsiao-Han Wang, MD, Yu-Ting Huang, MA, Chun-Yuan Chen, PhD, Ying-Chih Cheng, MD, Po-Hsiu Kuo, PhD, Yu-Chen Huang, MD, and Yu-Kang Tu, DDS, PhD*
- 398** Tildrakizumab efficacy, drug survival, and safety are comparable in patients with psoriasis with and without metabolic syndrome: Long-term results from 2 phase 3 randomized controlled studies (reSURFACE 1 and reSURFACE 2)  
Bottom line: Tildrakizumab efficacy was comparable and durable in patients with psoriasis with versus without metabolic syndrome for up to 3 years; safety was consistent with the known profile of tildrakizumab.  
*Mark G. Lebwohl, MD, Craig L. Leonardi, MD, Nehal N. Mehta, MD, MSCE, Alice B. Gottlieb, MD, PhD, Alan M. Mendelsohn, MD, Jeff Parnoo, MS, Stephen J. Rozzo, PhD, and M. Alan Menter, MD*

- 408**      **Mucocutaneous disease and related clinical characteristics in hospitalized children and adolescents with COVID-19 and multisystem inflammatory syndrome in children**  
 Bottom line: This study highlights novel mucocutaneous observations associated with SARS-CoV-2 infection, which may support recognition of infection and its potential relevance to prognosis and the development of diagnostic criteria for MIS-C.  
*Sergey Rekhtman, MD, PharmD, MPH, Rachel Tannenbaum, BS, Andrew Strunk, MA, Morgan Birabaharan, MD, Shari Wright, BS, and Amit Garg, MD*

- 415**      **Hypertrichotic patches as a mosaic manifestation of Proteus syndrome**  
 Bottom line: Most individuals with Proteus syndrome have hypertrichosis in an asymmetric distribution, a finding that should prompt consideration of this disorder and mosaic activation of phosphoinositide 3-kinase (PI3K)-protein kinase B (AKT) signaling.  
*Deeti J. Pithadia, BS, John W. Roman, MD, Julie C. Sapp, ScM, Leslie G. Biesecker, MD, and Thomas N. Darling, MD, PhD*

**Dermatologic Surgery**

- 425**      **Thrombotic complications with interruption of direct oral anticoagulants in dermatologic surgery**  
 Bottom line: This retrospective analysis suggests that perioperative interruption of direct oral anticoagulants appears to be safe and efficacious in dermatologic surgery.  
*Spyros M. Siscos, MD, Brett C. Neill, MD, Anjali Hocker Singh, CRA, and Thomas L. H. Hocker, MD*

**From the Academy**

- 432**      **Joint AAD–NPF Guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures**  
*Craig A. Elmets, MD (Co-Chair), Neil J. Korman, MD, PhD, Elizabeth Farley Prater, MD, Emily B. Wong, MD, Reena N. Rupani, MD, Dario Kivelevitch, MD, April W. Armstrong, MD, MPH, Cody Connor, MD, Kelly M. Cordoro, MD, Dawn M. R. Davis, MD, Boni E. Elewski, MD, Joel M. Gelfand, MD, MSCE, Kenneth B. Gordon, MD, Alice B. Gottlieb, MD, PhD, Daniel H. Kaplan, MD, PhD, Arthur Kavanaugh, MD, Matthew Kiselica, BA, BS, Daniela Kroshinsky, MD, MPH, Mark Lebwohl, MD, Craig L. Leonardi, MD, Jason Lichten, MD, Henry W. Lim, MD, Nehal N. Mehta, MD, Amy S. Paller, MD, Sylvia L. Parra, MD, Arun L. Pathy, MD, Michael Siegel, PhD, Benjamin Stoff, MD, Bruce Strober, MD, PhD, Jashin J. Wu, MD, Vidhya Hariharan, PhD, and Alan Menter, MD (Co-Chair)*

Reviews

- 471** Prevalence of asthma in patients with atopic dermatitis: A systematic review and meta-analysis  
 Bottom line: The mean prevalence of asthma among patients with atopic dermatitis was 25.7%. Physicians should be aware of this and address asthma symptoms in their patients with atopic dermatitis.  
*Nanna Ravnborg, MS, Danni Ambikaibalan, MD, Gaurav Agnihotri, MD, Shmuel Price, MD, Supriya Rastogi, MD, Kevin R. Patel, MD, Vivek Singam, MD, Yuki Andersen, MD, PhD, Anne-Sofie Halling, MD, Jonathan I. Silverberg, MD, PhD, MPH, Alexander Egeberg, MD, PhD, and Jacob P. Thyssen, MD, PhD, DMSc*
- 479** Role of phototherapy in the era of biologics  
 Bottom line: Despite therapeutic advancements, phototherapy still has a role as a safe, well-established, cost-effective treatment option; only dermatologists have the expertise and training to make this treatment available to our patients.  
*Angeli Eloise Torres, MD, Alexis B. Lyons, MD, Iltefat H. Hamzavi, MD, and Henry W. Lim, MD*
- 486** Occupational dermatitis to facial personal protective equipment in health care workers: A systematic review  
 Bottom line: A systematic review of facial occupational dermatoses due to personal protective equipment revealed that allergic and irritant contact dermatitis are most common, followed by acneiform eruptions and contact urticaria.  
*Jiade Yu, MD, Jennifer K. Chen, MD, Christen M. Mowad, MD, Margo Reeder, MD, Sara Hylwa, MD, Sarah Chisolm, MD, Cory A. Dunnick, MD, Ari M. Goldminz, MD, Sharon E. Jacob, MD, Peggy A. Wu, MD, MPH, Jonathan Zippin, MD, and Amber Reck Atwater, MD*

Research Letters

- 495** Dupilumab prevents flares in adults with moderate to severe atopic dermatitis in a 52-week randomized controlled phase 3 trial  
*Joseph F. Merola, MD, MMSc, Robert Sidbury, MD, MPH, Andreas Wollenberg, MD, Zhen Chen, PhD, Annie Zhang, MD, Brad Shumel, MD, and Ana B. Rossi, MD*
- 497** Retrospective analysis of laboratory abnormalities in patients prescribed terbinafine for onychomycosis  
*Yu Wang, BA, Solomon Geizhals, BA, and Shari R. Lipner, MD, PhD*
- 499** Feasibility and implementation of portable confocal microscopy for point-of-care diagnosis of cutaneous lesions in a low-resource setting  
*Esther E. Freeman, MD, PhD, Aggrey Semeere, MBChB, MMED, MAS, Miriam Laker-Oketta, MD, MSc, DTMH, DPPM, Priscilla Namaganda, MBChB, MMed, Hany Osman, MD, Robert Lukande, MB ChB, MMed, FCPATH, Devon McMahon, BA, Divya Seth, MD, Linda Oyesiku, MPH, Guillermo J. Tearney, MD, PhD, Salvador Gonzalez, MD, PhD, Milind Rajadhyaksha, PhD, R. Rox Anderson, MD, Jeffrey Martin, MD, MPH, and Dongkyun Kang, PhD*

- 502** Melanoma incidence and survival in patients with myelodysplastic syndrome: A matched cohort population-based study  
*Paola Barriera-Silvestrini, MD, David D. Xiong, BS, Steven Lewis, MS, MBA, and Thomas Knackstedt, MD*
- 505** Timing of PCR and antibody testing in patients with COVID-19—associated dermatologic manifestations  
*Esther E. Freeman, MD, PhD, Devon E. McMahon, BA, George J. Hruza, MD, MBA, Jules B. Lipoff, MD, Lars E. French, MD, Lindy P. Fox, MD, and Marlys S. Fassett, MD, PhD*
- 507** Chilblain-like lesions and COVID-19 infection: A prospective observational study at Spain's ground zero  
*Marta Feito-Rodríguez, PhD, Ander Mayor-Ibarguren, MD, Carmen Cámara-Hijón, PhD, Dolores Montero-Vega, MD, Guillermo Servera-Negre, MD, Elena Ruiz-Bravo, MD, Pilar Nozal, MD, José Luis Rodríguez-Peralto, PhD, Ana Belén Enguita, PhD, Luz Yadira Bravo-Gallego, MD, Mari Granados-Fernández, MD, Celia Fernández-Alcalde, MD, Álvaro Fernández-Heredero, MD, Marina Alonso-Riaño, MD, Víctor Jiménez-Yuste, PhD, Almudena Nuño-González, PhD, Raúl De Lucas-Laguna, MD, Eduardo López-Granados, PhD, and Pedro Herranz-Pinto, PhD*
- 510** Cutaneous findings in hospitalized and critically ill patients with COVID-19: A case series of 15 patients  
*Mark A. Strom, MD, Megan H. Trager, BA, Dmitriy Timerman, MD, Alexandra J. Coromilas, MD, Katy Burris, MD, Donald V. Belsito, MD, Ariel Eber, MD, Sophie Greenberg, MD, Sameera Husain, MD, Jesse M. Lewin, MD, Fludiona Naka, MD, Christina C. Patrone, MD, Aaron Coulon, MD, Chelsea Cooper, MD, Frederick B. Bartholomew, MD, Melissa Beck, MD, Margaret L. Dowd, MD, Courtney Ensslin, MD, Stephanie M. Gallitano, MD, Eric Loesch, MD, Dana M. Malajian, MD, Laura Melnick, MD, George W. Niedt, MD, Laura N. Uwakwe, MD, Ha Linh Vu, MD, Robert R. Walther, MD, Faramarz H. Samie, MD, PhD, and Larisa J. Geskin, MD*
- 511** COVID-19 and health care disparities: Innovative ways to meet the dermatologic needs of patients experiencing homelessness  
*Samantha M. Guhan, BA, Neera R. Nathan, MD, MSHS, Haya Raef, BA, Margaret Cavanaugh-Hussey, MD, MPH, and Jennifer K. Tan, MD*

- 513** Incidence of severe COVID-19 outcomes in psoriatic patients treated with systemic therapies during the pandemic: A Biobadaderm cohort analysis  
*Ofelia Baniandrés-Rodríguez, MD, PhD, Jaime Vilar-Alejo, MD, Raquel Rivera, MD, José Manuel Carrascosa, MD, PhD, Esteban Daudén, MD, PhD, Enrique Herrera-Acosta, MD, PhD, Antonio Sahuquillo-Torralba, MD, Fran J. Gómez-García, MD, Lula María Nieto-Benito, MD, Pablo de la Cueva, MD, PhD, José Luis López-Estebanz, MD, PhD, Isabel Belinchón, MD, PhD, Marta Ferrán Farrés, MD, PhD, Mercè Alsina, MD, PhD, Lourdes Rodríguez Fernández-Freire, MD, Gregorio Carretero, MD, PhD, Carmen García-Donoso, MD, Ferrán Ballescà, MD, Mar Llamas-Velasco, MD, PhD, Enrique Herrera-Ceballos, MD, PhD, Rafael Botella-Estrada, MD, PhD, Diana Patricia Ruiz-Genao, MD, Josep Riera-Monroig, MD, Miguel Ángel Descalzo Gallego, MSc, PhD, and Ignacio García-Doval, MD, PhD, and the BIOBADADERM Study Group*
- 517** Analysis of availability of online dermatology appointments during the COVID-19 pandemic  
*Lilly Gu, BS, Laura Xiang, BA, and Shari R. Lipner, MD, PhD*
- 520** Diagnostic and management considerations for “maskne” in the era of COVID-19  
*Wan-Lin Teo, MBBS, MRCS (UK), FAMS (Dermatology)*
- 522** Differences in dermatologic patient complexity based on practice setting  
*Christian Gronbeck, BA, Paula W. Feng, MD, and Hao Feng, MD, MHS*
- 524** Geographic variation in reduced minority representation at dermatology clinics in the Medicare population  
*Christian Gronbeck, BA, Paula W. Feng, MD, and Hao Feng, MD, MHS*
- 526** Treatment of nail psoriasis with intramatrix methotrexate: An uncontrolled prospective study of 20 patients  
*Paras Choudhary, MD, Rajesh Datt Mehta, MD, Bhikam Chand Ghiya, MD, and Divya Sharma, MD*
- 528** Chemoprevention of keratinocyte carcinoma and actinic keratosis in solid-organ transplant recipients: Systematic review and meta-analyses  
*Louis Y. Tee, MD, PhD, Rehena Sultana, MS, Steve Y. C. Tam, BS, and Choon Chiat Oh, MD*
- 530** CD30<sup>+</sup> leukemic cutaneous T-cell lymphoma  
*Ariana Ellis, BS, Luisa F. Christensen, MD, Timmie Sharma, MD, Howard Meyerson, MD, Honda Kord, MD, and Kevin D. Cooper, MD*
- 532** The association of frontal fibrosing alopecia with skin and hair care products: A survey-based case series of 56 patients seen at the Mayo Clinic  
*Reese L. Imhof, BA, Sydney C. Larkin, BA, Hafsa M. Cantwell, MD, Rochelle R. Torgerson, MD, PhD, and Stanislav N. Tolkachjov, MD*



- 534** Effect of statin use on incidence of eczema and atopic dermatitis: A retrospective cohort study  
*Kevin Cheung, BS, Edward M. Powers, MD, Julie McKillip, RN, BSN, and Jennifer G. Powers, MD*
- 536** Pain in dermatologic surgery: A prospective quantitative study  
*Eva van Loo, MD, Gabrielle Westerveld, MD, Patty J. Nelemans, PhD, and Nicole W. J. Kelleners-Smeets, MD, PhD*
- 538** Worsening skin damage in patients with cutaneous lupus erythematosus may predict development of systemic lupus erythematosus  
*Frances Walocko, MD, Samantha Black, BS, Scott Anderson, MS, Xilong Li, PhD, Beverley Adams-Huet, MS, and Benjamin F. Chong, MD, MSCS*
- 540** Management of immune checkpoint inhibitor–induced bullous pemphigoid  
*Zoe Apalla, PhD, Aimilios Lallas, PhD, Florentina Delli, MD, Elizabeth Lazaridou, PhD, Stavroula Papalampou, MD, Stavroula Apostolidou, MD, Maria Gerochristou, MD, Dimitrios Rigopoulos, PhD, Alexandros Stratigos, PhD, and Vassiliki Nikolaou, PhD*
- 543** Efficacy and safety of hydroxychloroquine for treatment of patients with rosacea: A multicenter, randomized, double-blind, double-dummy, pilot study  
*Ben Wang, MD, Xin Yuan, MD, Xin Huang, MD, Yan Tang, MD, Zhixiang Zhao, MD, Bin Yang, MD, Baoqi Yang, MD, Yue Zheng, MD, Chao Yuan, MD, Hongfu Xie, MD, PhD, and Ji Li, MD, PhD*
- 545** The role of thymus and activation-regulated chemokine as a marker of severity of atopic dermatitis  
*Himadri, MD, Renu George, MD, Lydia Mathew, MD, Vanitha Shanmugam, MSc, Thenmozhi Mani, PhD, and Lakshmanan Jeyaseelan, PhD*
- 547** One-year real-world clinical effectiveness, safety, and laboratory safety of dupilumab in Japanese adult patients with atopic dermatitis: A single-center retrospective study  
*Hideaki Uchida, MD, Masahiro Kamata, MD, PhD, Aika Kato, MD, Itsumi Mizukawa, MD, Ayu Watanabe, MD, Ai Agematsu, MD, Mayumi Nagata, MD, Saki Fukaya, MD, Kotaro Hayashi, MD, PhD, Atsuko Fukuyasu, MD, Takamitsu Tanaka, MD, PhD, Takeko Ishikawa, MD, PhD, Takamitsu Ohnishi, MD, PhD, and Yayoi Tada, MD, PhD*
- 550** Large nuclear size correlated with better overall survival, Merkel cell polyomavirus positivity, and terminal deoxynucleotidyl transferase expression in Merkel cell carcinoma  
*Jakob M. T. Moran, MD, Przemyslaw Biecek, PhD, Piotr Donizy, MD, PhD, Cheng-Lin Wu, MD, Janusz Kopczynski, MD, PhD, Małgorzata Pieniazek, MD, PhD, Janusz Ryś, MD, PhD, and Mai P. Hoang, MD*

- 552** Efficacy and safety of secukinumab in moderate to severe palmoplantar pustular psoriasis over 148 weeks: Extension of the 2PRECISE study  
*Ulrich Mrowietz, MD, Hervé Bachelez, MD, Arthur David Burden, MD, FRCP, Michael Rissler, PhD, Christian Sieder, PhD, Roberto Orsenigo, MD, and Piotr Jagiello, MD, PhD*
- 554** A pilot study of the impact of facial skin protectants on qualitative fit testing of N95 masks  
*Ai-Tram N. Bui, BA, Zizi Yu, BA, Karen Lee, BS, Sara J. Li, BS, William G. Tsiaras, MD, PhD, Sherry H. Yu, MD, Nicole R. LeBoeuf, MD, MPH, and Arash Mostaghimi, MD, MPA, MPH*
- 556** Dermatoses of the world: Burden of skin disease and associated socioeconomic status in the world  
*Rachel L. Giese, DO, Sino Mehrmal, BSN, Prabhdeep Uppal, MS, Maria E. Delost, PhD, and Gregory R. Delost, DO*
- 559** A single-center, retrospective record review of malignancy prevalence in patients with dermatomyositis with anti-transcription intermediary factor 1 $\gamma$  antibodies via line immunoassay versus immunoprecipitation  
*Skylar Westerdahl, BS, Christopher M. Hull, MD, Jennie T. Clarke, MD, Christopher B. Hansen, MD, and Jamie L. W. Rhoads, MD, MS*
- 561** Smoking and risk of adult-onset atopic dermatitis in US women  
*Deanna E. Morra, MPH, Eunyoung Cho, ScD, Tricia Li, MD, MS, Carlos A. Camargo, Jr, MD, DrPH, Abrar A. Qureshi, MD, MPH, and Aaron M. Drucker, MD, ScM*
- 563** COVID-19 outbreak and autoimmune bullous diseases: A systematic review of published cases  
*Michael Kasperkiewicz, MD*
- 568** Sites of distant metastasis in Merkel cell carcinoma differ by primary tumor site and are of prognostic significance: A population-based study in the Surveillance, Epidemiology, and End Results database from 2010 to 2016  
*Nolan J. Maloney, MD, Kevin A. Nguyen, MS, Daniel Q. Bach, MD, MPH, and Lisa C. Zaba, MD, PhD*
- 570** A retrospective cohort study of comprehensive peripheral and deep margin assessment in Merkel cell carcinoma: Standard margins may be unreliable  
*Eric Wilkerson, MD, Rebecca Knackstedt, MD, PhD, Allison Vidimos, RPh, MD, Brian Gastman, MD, and Thomas Knackstedt, MD*

- 572** Accuracy of commercial panels to evaluate myositis autoantibodies: A single-institution perspective  
*Adarsh Ravishankar, BS, Josef S. Concha, MD, Daisy Yan, BA, Christina E. Bax, BA, Andrea C. Yeguez, BA, Livia Casciola-Rosen, PhD, and Victoria P. Werth, MD*
- 574** A national webinar for dermatology applicants during the COVID-19 pandemic  
*Caitlin M. Brumfiel, MS, Itisha S. Jefferson, BS, Albert G. Wu, MS, Jennifer L. Strunck, BS, Surya Veerabagu, BS, Krysta Lin, BS, Robert T. Brodell, MD, and Ilana S. Rosman, MD*
- 576** The continuing impact of COVID-19 on dermatology practice: Office workflow, economics, and future implications  
*Graham H. Litchman, DO, MS, Justin W. Marson, MD, and Darrell S. Rigel, MD, MS*
- 579** Treatment practices for psoriasis and how they are changing  
*Suraj Muddasani, BS, Alan B. Fleischer, Jr, MD, and Steven R. Feldman, MD, PhD*
- 581** Tofacitinib for cutaneous and pulmonary sarcoidosis: A case series  
*Karolina L. Kerkemeyer, BHlthSci, MBBS (Hons), Nekma Meah, MBChB, MRCP, and Rodney D. Sinclair, MD, FACD*
- 583** Hydroxychloroquine prescribing habits and impact of the COVID-19 pandemic  
*Drew Kuraitis, MD, PhD, and Andrea Murina, MD*

- 
- Ethics Journal Club** **585** The ethics of navigating an inappropriately canceled inpatient dermatology consultation  
*Abraham M. Korman, MD, and Jane M. Grant-Kels, MD*

- 
- Correction** **586** Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 5. Guidelines of care for the treatment of psoriasis with phototherapy and photochemotherapy. *J Am Acad Dermatol.* 2010;62(1):114-135.

---

**JAAD ONLINE**

Available at <http://www.jaad.org>

- 
- Clinical Pearl** **e71** Use of a dental mirror in the examination of oral pemphigus  
*Jerene Mathews, MD, Logamoorthy Ramamoorthy, MBBS, and Laxmisha Chandrashekar, MD, DNB*

- 
- Therapeutic Pearl** **e73** A novel simple biopsy-site identification tool  
*Rosanne Ottevanger, MD, Marieke E. Weijns, MD, and Roel E. Genders, MD, PhD*
-

<b>Surgical Pearls</b>	<b>e75</b>	Bone wax as an ideal dressing for auricle concha <i>Héctor Perandones-González, MD, Paula Fernández-Canga, MD, and Manuel Ángel Rodríguez-Prieto, MD</i>
	<b>e77</b>	Single-handed vampire facial: Combining microneedling with platelet-rich plasma for single-hand use <i>Vikas Pathania, MD, Bhavni Oberoi, MBBS, Prerna Shankar, MD, and Siddharth Bhatt, MBBS</i>
	<b>e79</b>	Creating slits to the right depth: Innovative use of micropore tape for depth control on an 18-gauge needle in hair restoration surgery <i>Vikas Pathania, MD, and Siddharth Bhatt, MBBS</i>
	<b>e81</b>	Indwelling long-line method for suturing lower eyelid incisions <i>Xingfan Mo, MD, Jingjing Li, MD, Fanghua He, MD, Minzhi Wu, MD, and Liang Zhao, MD</i>
	<b>e83</b>	When you need a third hand, tape and gauze will do <i>Mohammed I. AlJasser, MBBS, FRCPC, and Gillian de Gannes, MD, FRCPC</i>
<hr/>		
<b>Technology Pearl</b>	<b>e85</b>	Panoramic trichoscopy <i>Leonardo Spagnol Abraham, MD, MSc, Sofia Sales Martins, MD, Rodrigo Pirmez, MD, and Bruna Duque-Estrada, MD</i>
<hr/>		
<b>Notes &amp; Comments</b>	<b>e87</b>	A response to "Male balding is a major risk factor for severe COVID-19" <i>Akshitha Thatiparthi, BS, Jeffrey Liu, BS, Amylee Martin, BS, and Jashin J. Wu, MD</i>
	<b>e89</b>	Reply to letter to the editor: "A response to 'Male balding is a major risk factor for severe COVID-19'" <i>Ahmed Yousaf, BA, and Michael S. Kolodney, MD, PhD</i>
	<b>e91</b>	The underrepresentation of "COVID toes" in skin of color: An example of racial bias or evidence of a tenuous disease association? <i>Abigail Cline, MD, PhD, Juliana Berk-Krauss, MD, Ashley Keyes Jacobs, MD, Maira Fonseca, MD, Julia Wu, MD, Falguni Asrani, MD, Amilcar Rizzo, MD, Janet Moy, MD, Marian Russo, MD, Sharon Glick, MD, Rachel Blasiak, MD, Beth N. McLellan, MD, and Shoshana Marmon, MD, PhD</i>
	<b>e93</b>	Commentary on "Role of phototherapy in the era of biologics" <i>Aysenur Botsali, MD</i>
	<b>e95</b>	Response to: "Commentary on 'Role of phototherapy in the era of biologics'" <i>Angeli Eloise Torres, MD, Alexis B. Lyons, MD, Iltefat H. Hamzavi, MD, and Henry W. Lim, MD</i>

- e97** Volunteer and work experiences among dermatology residency applicants  
*Swetha Atluri, BS, Justine R. Seivright, BS, Vivian Y. Shi, MD, and Jennifer L. Hsiao, MD*
- e99** The importance of publications, research, volunteer, and work experience in dermatology residency applicants  
*Abigail Cline, MD, PhD, Adrian Pona, MD, Maureen Ezekor, MD, William W. Huang, MD, MPH, and Steven R. Feldman, MD, PhD*
- e101** Oral syphilis  
*José Alcides Almeida de Arruda, DDS, MSc, Isabella Bittencourt do Valle, DDS, MSc, Ricardo Alves Mesquita, DDS, PhD, and Tarcília Aparecida Silva, DDS, PhD*
- e103** COVID-19 compels closer scrutiny of disparities in dermatology  
*Laurie A. Temiz, BA, Lynn McKinley-Grant, MD, Donald A. Glass II, MD, PhD, and Valerie M. Harvey, MD, MPH*
- e105** Depression screening for patients with acne in the United States compared to other skin diseases, 2005 to 2016  
*Nishadh Sutaria, BS, Jordan R. Pollock, BS, and Shawn G. Kwatra, MD*
- e107** Reply to "Depression screening for patients with acne in the United States compared to other skin diseases, 2005 to 2016"  
*Matthew T. Taylor, BA, and John S. Barbieri, MD, MBA*
- e109** Implications of increasing publication trends in dermatology on individuals from disadvantaged backgrounds and those without a home dermatology program  
*Ramiro Rodriguez, BS, Alfredo Siller, Jr, MD, Amit G. Pandya, MD, and Arturo R. Dominguez, MD*
- e111** Reply to Letter to the Editor  
*Abigail Cline, MD, PhD, Adrian Pona, MD, William W. Huang, MD, MPH, and Steven R. Feldman, MD, PhD*
- e113** Unethical use of imiquimod as a comparator group in a randomized clinical trial of children with molluscum contagiosum  
*Kenneth A. Katz, MD, MSc, MSCE*
- e115** Missing the mark on patient comprehension  
*Daniela Sanchez, BS, Mayra B. C. Maymone, MD, DSc, and Neelam A. Vashi, MD*
- e117** Reply to: "Missing the mark on patient comprehension"  
*Brett C. Neill, MD, Edward W. Seger, MD, MS, Jace J. Rickstrew, MD, and Anand Rajpara, MD*

**lotaderma**
**e119**
**lotaderma (#324)**
*Robert I. Rudolph, MD, FACP*

To access the current version of the Information for Authors, Transfer of Copyright Form, Authorship Declaration Form, Conflict of Interest Disclosure, and Authors' Rights Statement, as well as many other pertinent documents, please visit our website at [www.jaad.org/content/auth\\_page](http://www.jaad.org/content/auth_page).

Full text access to Journal of the American Academy of Dermatology Online is now available for Academy members and all print subscribers. To activate your online subscription, please visit Journal of the American Academy of Dermatology Online by pointing your browser to <http://www.jaad.org>.

**Icon Key**


CME article


 Video content available at <http://www.jaad.org>

 An interview with the author is available by podcast at: <https://account.aad.org/Library/Podcasts>


MOC credits available

**Early online publication: Articles in press**

The *Journal of the American Academy of Dermatology* posts in-press articles online before they appear in the print edition of the *Journal*. These Articles in Press are available from both the JAAD website ([www.jaad.org](http://www.jaad.org)) and Science Direct ([www.sciencedirect.com](http://www.sciencedirect.com)).

To access Articles in Press, simply click the Articles in Press link.

**JAAD Case Reports**

The *Journal of the American Academy of Dermatology* no longer publishes Case Reports. These can now be found in our new open access journal, JAAD Case Reports, at <http://www.jaadcasereports.org>.